Dernières nouvelles pour Medtronic (NYSE:MDT) Stock

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

MEDTRONIC ORD

Stryker (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities. Still, recent months in 2024 have been particularly active for Stryker when it comes to acquisitions.
Since the beginning of July, the company has closed on or announced purchases of five companies. I&#39;ll dive into what Stryker does and the most important of these acquisitions to help determine whether they make the stock a buy.
<h2>Stryker: A Highly Diversified Medical Device Company</h2>
Stryker has two reportable segments: MedSurg &amp; Neurotechnology and Orthopedics &amp; Spine. MedSurg provides surgical tools, including minimally invasive devices. These include small cameras used in surgeries. Neurotechnology offers tools for skull and brain surgeries, including stroke treatments. In 2023, this segment accounted for 58% of the company&#39;s total revenue.
The other segment revolves around bodily implants. Orthopedics includes hip, knee, and shoulder implants to replace these joints. The company&#39;s Mako system provides robotics-assisted replacement of these joints. It has similarities to Intuitive Surgical&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) da Vinci system, but the two specialize in different treatment areas.
This segment also provides trauma and extremity implants. Trauma refers to implants used to help repair large broken bones like those in the arms and legs. Extremity implants help repair joints and bones in the hands and feet. It also provides spinal implants. This segment accounted for 42% of revenue in 2023.
<h2>Breaking Down Stryker&#39;s Recent Acquisitions</h2>
I&#39;ll focus on two of Stryker&#39;s recent acquisitions, NICO and Care.ai.
The NICO acquisition now gives Stryker ownership of minimally invasive devices that are used to surgically treat intracerebral hemorrhage (ICH). ICH is the deadliest form of stroke and affects 3.4 million people annually. The current care standard for ICH is medical management. This means doctors keep the patient stable while they hope the body can remove the blood clot over time.
The New England Journal of Medicine published a study where the NICO technology cut patient mortality rates by nearly in half compared to medical management. Additionally, the patients treated using NICO had significantly better quality of life outcomes. Given the large number of patients who suffer from ICH and the impressive efficacy of NICO technology, this feels like a strong purchase.
The care.ai purchase allows Stryker to offer its hospital and health provider customers tools to more efficiently monitor the status of patients. This allows these customers to make better decisions about how to allocate resources across patients. For example, patients can use AI chatbots to assess their condition. They can check whether they need urgent medical care or not.
The company&#39;s technology can also improve the monitoring of patients while they are in the healthcare facility. Its &quot;smart room&quot; technology involves installing sensors that use AI to better monitor the condition of patients. These features can help Stryker&#39;s customers better prioritize staff and resources in a facility. They aim to improve patient outcomes and satisfaction.
Overall, this could create value for Stryker customers. However, I am less sold on it compared to NICO. Just because a company uses AI in its offerings doesn&#39;t mean it is truly providing differentiated value compared to what already exists.
In the near term, these acquisitions will not impact the company&#39;s financial results. This is likely the case, as the financial details of these acquisitions were not disclosed. The Securities and Exchange Commission (SEC) does not require publicly traded companies to disclose these details unless the acquisitions are expected to have a material impact on the company&#39;s financial statements. Still, they could definitely create value for the company over the long term.
I especially like the NICO acquisition, and it could be a good thing that the company did not have to disclose the price. It might suggest that they were able to acquire the asset at a reasonable cost.
<h2>Stryker Is Expected to See Robust Earnings Growth</h2>
Analysts expect strong earnings growth over the next two years, especially versus its peers. Analysts expect a 12% annual growth in trailing twelve months earnings per share. That is over double the rate of one of its main competitors, Medtronic (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>).
Two Wall Street analysts raised their price target for Stryker in October. Their average price target implies an upside of 7% for the stock. Stryker remains a strong player in its industry, but these acquisitions don&#39;t move the needle on the stock for me right now.
The article &quot;<a href="https://www.marketbeat.com/originals/strykers-acquisition-spree-double-digit-growth-on-the-horizon/">Stryker&#39;s Acquisition Spree: Double-Digit Growth on the Horizon</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

News

Price Target

Offerings

Markets

Analyst Ratings

Trading Ideas

ISRG

Stryker's Acquisition Spree: Double-Digit Growth on the Horizon

RBC Capital analyst Shagun Singh upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Sector Perform to Outperform and raises the price target from $98 to $105.

Upgrades

RBC Capital Upgrades Medtronic to Outperform, Raises Price Target to $105

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $93.33, along with a high estimate of $106.00 and a low estimate of $85.00. Observing a 2.71% increase, the current average has risen from the previous average price target of $90.87. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421229_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Perform</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>All You Need to Know About Medtronic</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Understanding the Numbers: Medtronic's Finances</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin excels beyond industry benchmarks, reaching 13.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Medtronic's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.58, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Assess Medtronic: What You Need To Know

RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Sector Perform and raises the price target from $92 to $98.

RBC Capital Maintains Sector Perform on Medtronic, Raises Price Target to $98

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) initiated a recall Friday to address potential battery life issues with <a href="https://www.benzinga.com/pressreleases/24/10/n41181874/voluntary-recall-notifying-medtronic-insulin-pump-users-of-potential-risks-of-shortened-pump-batte" target="_blank" rel="noreferrer noopener">its insulin pumps</a>.
As of July 31, the company has advised customers to pay close attention to their pumps&#8217; battery alerts and alarms.
The action follows reports of shortened battery life, which Medtronic linked to pumps that had been dropped or impacted.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40737587/medtronic-recalls-some-video-laryngoscopes-due-to-increased-risk-for-battery-overheat-explosion" rel="noreferrer noopener">Medtronic Recalls Some Video Laryngoscopes Due To Increased Risk For Battery Overheat, Explosion</a>.
This damage to internal electrical components may result in the pump stopping insulin delivery earlier than expected, posing risks such as hyperglycemia (high blood sugar) or diabetic ketoacidosis (DKA).
DKA is a complication of diabetes that occurs when the body doesn&#8217;t have enough insulin to use blood sugar for energy.
Medtronic&#8217;s investigation revealed that even a single drop could significantly reduce battery life, either immediately or over time.
This issue persists within the MiniMed 600 and 700 pumps even after the battery is replaced.
Additionally, battery alerts and alarms may not provide the usual warning before the pump stops insulin delivery, increasing the need for users to replace the battery as soon as the &#8220;Low Battery Pump&#8221; alarm is triggered.
Medtronic strongly advises users to carry extra AA lithium, alkaline, or fully charged NiMH batteries as a precaution.
The issue is serious, as Medtronic has received 170 reports of hyperglycemia exceeding 400 mg/dL and 11 reports of DKA in the U.S. between January 2023 and September 2024, possibly related to this problem.
The FDA has classified the action as a class I recall. That&#8217;s the most serious type of recall due to potential adverse health consequences.
Medtronic users who experience shortened battery life should contact their local support team to assess whether a replacement pump is needed.
In 2021, Medtronic expanded the Class I recall of its MiniMed 600 series insulin pumps. The company offered to replace all of them with a <a href="https://www.benzinga.com/news/21/10/23266202/medtronic-expands-recall-of-minimed-600-series-insulin-pumps" target="_blank" rel="noreferrer noopener">clear retainer ring</a>.
Price Action: MDT stock closed at $87.72 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41183612/nvidias-top-brass-unloaded-significant-stock-in-2024-amid-ai-spending-and-chip-delays" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Top Brass Unloaded Significant Stock In 2024 Amid AI Spending and Chip Delays</a>.</li>
</ul>
Image: Wikimedia Commons

Health Care

General

Medtronic Recalls MiniMed Pump Due To Battery Life Concerns

Medtronic Voluntarily Issued A Field Action Notifying Of Its MiniMed 600 Series Or 700 Series Insulin Pumps With Potential Risks Of Shortened Pump Battery Life

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 23.26% since its last report. The company recently reported that it has 12.70 million shares sold short, which is 0.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727893813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Medtronic's Recent Short Interest

Evercore ISI Group analyst Vijay Kumar maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and raises the price target from $100 to $104.

Evercore ISI Group Maintains Outperform on Medtronic, Raises Price Target to $104

Citigroup analyst Joanne Wuensch maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $85 to $92.

Citigroup Maintains Neutral on Medtronic, Raises Price Target to $92

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect&#x2122; Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.
Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia.
"Real-world evidence on chronic lesion formation and durability is critical as use of PFA for the treatment of Afib rapidly increases, making these results impactful and timely for the electrophysiology community," said Devi Nair, M.D., FHRS, Director of Cardiac Electrophysiology &amp; Research, St. Bernard's Medical Center &amp; Arrhythmia Research Group, Jonesboro, Arkansas. "Our research shows that treatment with PulseSelect results in durable lesion formation, which is the cornerstone of successful pulmonary vein isolation and an important addition to previous evidence establishing the safety and effectiveness of this technology."
About the Study A total of 25 AFib patients with persistent or paroxysmal AFib (56% paroxysmal, 52% male, 69±9 years) undergoing pulmonary vein isolation (PVI) with the PulseSelect PFA System were evaluated. Invasive remapping conducted in all patients (57±9 days post-ablation) demonstrated durable isolation in 98% of PVs (102/104), and 96% of patients (24/25) had all veins isolated.
All index ablation procedures were conducted using intracardiac echocardiography and electroanatomical mapping (EAM) without fluoroscopy. General anesthesia was used in 24 of 25 patients, and all patients were discharged on the same day. Average skin-to-skin procedure time was 36 minutes. Acute PV isolation was achieved in 100% of patients. There were no complications during an average follow-up of 74 days.
PulseSelect Global Expansion Broad adoption of PulseSelect continues globally, with more than 10,000 cases performed worldwide. In the Asia Pacific (APAC) region, milestones include regulatory approvals in China and Australia and launch in Japan following reimbursement approval.
Prof. Hiroshi Tada, Professor of the Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Japan, and President of the Japanese Heart Rhythm Society, said "PulseSelect is the first PFA catheter to receive reimbursement approval in Japan based on clinical trial results that include Japanese patients. We believe that the future widespread availability of this breakthrough technology under insurance coverage will be of great significance in the history of arrhythmia treatment in Japan."
"These important results clearly address the durability question and add to the real-world evidence for PulseSelect," said Rebecca Seidel, president, Cardiac Ablations Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "With expansion in new markets across the Asia Pacific region, physicians around the world are experiencing the benefits of PulseSelect, including proven safety, efficacy, efficiency and now durability as well. We are thrilled to provide this important tool to physicians for the treatment of patients with AFib."
AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide.1 Afib is a progressive disease, often beginning as paroxysmal AFib (presents intermittently) and progressing to persistent (lasts for more than 7+ days without stopping). As the disease progresses, the risk of serious complications including heart failure, stroke and risk of death increases.2-5

Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability

Investors with a lot of money to spend have taken a bearish stance on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MDT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Medtronic.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $30,528, and 9, calls, for a total amount of $634,635.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $82.5 and $97.5 for Medtronic, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Medtronic's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medtronic's whale activity within a strike price range from $82.5 to $97.5 in the last 30 days. 
<h3>Medtronic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121678_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.19</td>
<td>$1.19</td>
<td>$90.00</td>
<td>$143.3K</td>
<td>7.6K</td>
<td>1.7K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.16</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$92.50</td>
<td>$86.9K</td>
<td>592</td>
<td>1.6K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.19</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$92.50</td>
<td>$63.9K</td>
<td>592</td>
<td>960</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.19</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$92.50</td>
<td>$63.9K</td>
<td>592</td>
<td>660</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.2</td>
<td>$2.11</td>
<td>$2.11</td>
<td>$92.50</td>
<td>$63.3K</td>
<td>592</td>
<td>60</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
After a thorough review of the options trading surrounding Medtronic, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Medtronic's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,862,431, with MDT's price up by 0.74%, positioned at $90.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 57 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Medtronic Unusual Options Activity For September 23

AXNX

Reported Earlier, Axonics Prevails In Patent Dispute With Medtronic, Jury Confirms No Infringement On Three Patent

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has risen 22.86% since its last report. The company recently reported that it has 16.50 million shares sold short, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726166710_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.57%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Medtronic's Recent Short Interest

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/10/final-trades-3m-visa-medtronic-and-the-sphd.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management named 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), which <a href="https://www.benzinga.com/quote/MMM/analyst-ratings">recorded gains on Tuesday</a>.
On Sept. 6, Morgan Stanley analyst Chris Snyder initiated coverage on 3M with an Underweight rating and announced a price target of $125.
Kevin Simpson of Capital Wealth Planning said he likes Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>).
On Sept. 4, Compass Point analyst Dominick Gabriele initiated coverage on Visa with a Buy rating and announced a price target of $319.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) has a 3% dividend yield.
On Aug. 20, Medtronic reported better-than-expected results for its first quarter. The company posted first-quarter 2025 sales of $7.92 billion, beating the consensus of $7.89 billion. The medical device maker reported adjusted EPS of $1.23, beating the consensus of $1.20. Revenue increased 2.8% year over year, as reported, and 5.3% organic.
Liz Young of SoFi named Invesco S&amp;P 500 High Dividend Low Volatility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHD#NYSE">SPHD</a>) as her final trade.
Price Action:
<ul>
<li>3M gained 1.3% to close at $130.09 during Tuesday's session.</li>
<li>Visa shares fell 0.1% to settle at $285.34 on Tuesday.</li>
<li>Medtronic shares rose 0.4% to close at $90.99.</li>
<li>Invesco S&amp;P 500 High Dividend Low Volatility ETF rose 0.2% during Tuesday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock">Jim Cramer Says AES Is &#8216;Very Inexpensive&#8217;, Recommends Buying This Industrial Stock</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

SPHD

3M, Visa, Medtronic And More On CNBC's 'Final Trades'

NDAQ

CNBC Halftime Report Final Trades: Nasdaq, Visa, Medtronic, Invesco S&P 500 High Dividend Low Volatility ETF

Thursday, Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) said it is recalling certain devices and updating use instructions for another due to the possibility that the battery may deplete below its <a target="_blank" href="https://www.benzinga.com/quote/MDT" rel="noreferrer noopener">designed threshold</a>.
If this happens, it increases the risk of battery instability and may lead to increased battery temperature and a potential explosion.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40462317/medical-devices-giant-medtronic-q1-earnings-revenue-and-eps-beat-lifts-annual-guidance-marginally-o" rel="noreferrer noopener">Medical Devices Giant Medtronic Q1 Earnings: Revenue And EPS Beat, Lifts Annual Guidance Marginally On Sustained Growth From New Product Launches</a>.
The use of the affected product may cause serious adverse health consequences, including burns, cuts (lacerations), scarring and other tissue injuries, tooth loss, eye injury, damaged hearing (impairment or acoustic shock), or ringing in the ears (tinnitus), respiratory failure, lack of oxygen to the body (hypoxia), scarring, and death.&nbsp;
There has been one reported injury. There have been no reports of death.&nbsp;&nbsp;
This&nbsp;<a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/laryngoscope-recall-medtronic-removes-certain-mcgrath-mac-video-laryngoscopes-updates-use" rel="noreferrer noopener">recall</a> involves removing certain devices from where they are used or sold.&nbsp;The FDA has identified this recall as the most serious type.
This&nbsp;recall&nbsp;also involves updating instructions for using other models of these devices.
The McGrath MAC and MAC EMS Video Laryngoscopes are used to help care providers see into the trachea during a medical procedure. The devices include a light source and a miniature camera to view the voice box (larynx) during&nbsp;laryngoscopy, a procedure that allows a doctor to examine the larynx (voice box) and nearby structures.
Wednesday, Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/lung-therapy-component-recall-baxter-healthcare-corporation-recalls-certain-volara-system-single" rel="noreferrer noopener">said</a> it would recall certain Single-Patient Use Circuits and Blue Ventilator Adapter Assemblies due to reports that the handset plug within these components may disconnect from the nebulizer port on the blue ventilator adapter.
When using the Volara system in line with a ventilator and without a nebulizer connected to the blue ventilator adapter, the handset plug is required for proper operation and gas flow.
If the plug is disconnected, the ventilator may not provide enough ventilation to the patient.
The Volara System is intended for use with patients who are using a ventilator to help them breathe.
The Single Patient Use Circuit and Blue Adapter Assembly are patient circuit components that connect the Volara System to the ventilator. They are sold separately from the system.&nbsp;
Price Action: MDT stock is down 1.36% at $89.79 at last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40736850/shell-backs-climate-technology-start-up-for-emissions-reduction-report" target="_blank" rel="noreferrer noopener">Shell Backs Climate Technology Start-up for Emissions Reduction: Report</a>.</li>
</ul>

Equities

Medtronic Recalls Some Video Laryngoscopes Due To Increased Risk For Battery Overheat, Explosion

Biotech

FDA Says Abbott Diabetes Care Inc. Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings; Medtronic Removes Some McGRATH Mac Video Laryngoscopes, Updates Use Instructions For Others Due To Increased Risk For Battery Overheat & Explosion

PaceMate&#xAE;, a pioneer in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pacemate.com&amp;esheet=54113436&amp;newsitemid=20240827737585&amp;lan=en-US&amp;anchor=cardiac+data+management&amp;index=1&amp;md5=4618706a54a5bcdd543d536a401065e4">cardiac data management</a> and remote monitoring, announced today the acquisition of the Paceart Optima&#x2122; system, an on-premises cardiac workflow solution from Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) This strategic move significantly expands PaceMate's reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate's ability to provide the leading and most comprehensive <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpacemate.com%2F&amp;esheet=54113436&amp;newsitemid=20240827737585&amp;lan=en-US&amp;anchor=cardiac+remote+monitoring+solution&amp;index=2&amp;md5=1f61f71f5716c49904c4290635327636">cardiac remote monitoring solution</a>, continuing its position as the preferred partner in advanced cardiac data management.

Asset Sales

PaceMate Acquires Medtronic's Paceart Optima System; No Financial Terms Disclosed

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold and raises the price target from $85 to $90.

Truist Securities Maintains Hold on Medtronic, Raises Price Target to $90

Barclays analyst Matt Miksic maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and raises the price target from $104 to $105.

Barclays Maintains Overweight on Medtronic, Raises Price Target to $105

MedTech is a promising market driven by rising disease prevalence, innovative healthcare solutions, and significant growth in digital health technologies. Thus, adding strong MedTech stocks like Becton, Dickinson (BDX), Abbott (ABT), and Medtronic (MDT) to your watchlist could be wise as innovation in healthcare accelerates. Read more… As the global rise in diseases and patients drives the need for advanced healthcare solutions, the demand for medical devices, therapies, and high-quality treatments grows to improve outcomes, reduce costs, and enhance access to care. With MedTech constantly innovating to meet these challenges, the industry presents a vast market with promising investment opportunities.
Therefore, as innovation in healthcare soars, investors could consider keeping an eye on fundamentally strong MedTech stocks like Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>), Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>), and Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>).
The MedTech market is rapidly evolving and driven by trends such as remote care and personalized treatment. This growth is spurring investments in digital therapeutics, bioprinting, biometric wearables, digital health technologies, and 3D printing. These innovations improve patient monitoring and facilitate swift diagnosis and medical support, resulting in high demand in the healthcare sector.
MedTech has transformed the cardiovascular, orthopedic, neurological, urological, and diabetes sectors. Looking ahead, it will play a crucial role in enabling doctors to monitor patients' health and deliver improved care, reducing the reliance on hospital admissions and surgeries. Consequently, the global medical devices market is expected to reach $886.80 billion by 2032, with a robust <a href="https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085">CAGR of 6.3%</a>.
Furthermore, the healthcare sector is generating vast amounts of data that can enhance patient care. AI adoption is streamlining data management, optimizing electronic health records, and playing a crucial role in early disease detection and medical imaging. As a result, the global AI in medical devices market is projected to reach <a href="https://blog.marketresearch.com/artificial-intelligence-in-medical-devices-market-set-for-unprecedented-growth">$97.07 billion by 2028</a>, growing at a remarkable CAGR of 44.4%.
Considering these conducive trends, let's analyze the fundamentals of the three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks mentioned above, beginning with the third choice.
Stock #3: Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>)
BDX develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
On September 18, 2024, BDX announced the commercial release of the BDX Neopak XtraFlow Glass Prefillable Syringe and expanded production capacity for its BDX Neopak Glass Prefillable Syringe platform. These advancements aim to enhance the injection experience for biologic therapies and meet growing market demand.
On September 3, 2024, BDX announced the completion of its acquisition of Edwards Lifesciences' Critical Care product group, now renamed BDX Advanced Patient Monitoring. This acquisition enhances BDX's smart connected care solutions with advanced AI-enabled monitoring technologies.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a>, BDX's 25.77% is 304.7% higher than the 6.37% industry average. Likewise, its 3.65% trailing-12-month Capex / Sales is 10.4% higher than the 3.30% industry average. Its 14.23% trailing-12-month EBIT margin is 403.4% higher than the 2.83% industry average.
During the third quarter ended June 30, 2024, BDX's adjusted revenues increased 3.7% year-over-year to $5.06 billion. Similarly, its operating income grew 9.7% from the prior year to $602 million. The company's net income was $487 million, reflecting a 19.7% year-over-year growth, and its adjusted EPS rose 18.2% to $3.50.
Street expects BDX's EPS and revenue for the quarter ended September 30, 2024, to increase 10.2% and 5.2% year-over-year to $3.77 and $5.35 billion, respectively. It surpassed Street EPS estimates in three of the trailing four quarters. Over the past three months, the stock has gained 3.2% to close the last trading session at $241.10.
BDX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #26 out of 134 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. It has a B grade for Growth, Stability, and Sentiment. <a href="https://stocknews.com/stock/BDX/">Click here</a> to see BDX's ratings for Value, Momentum, and Quality.
Stock #2: Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT and its subsidiaries discover, develop, manufacture, and sell healthcare products worldwide. They operate in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
On August 27, 2024, ABT expanded its Pure Bliss by Similac line to include European-made and USDA-certified organic infant formulas, offering the first organic liquid formula available at U.S. retail stores. These products provide gentle, complete nutrition with ingredients like A2 milk and milk sourced from Irish farms.
On August 7, 2024, ABT announced a global partnership with MDT to combine its FreeStyle Libre glucose monitoring system with MDT's insulin delivery devices, improving diabetes management.
In terms of the trailing-12-month Capex / Sales, ABT's 5.52% is 66.9% higher than the 3.30% industry average. Its 13.23% trailing-12-month levered FCF margin is 759.5% higher than the 1.54% industry average. Also, its 17.98% trailing-12-month EBIT margin is 536.1% higher than the 2.83% industry average.
For the first half that ended on June 30, 2024, ABT's net sales rose 3.1% year-over-year to $20.34 billion. Its operating earnings grew marginally from the year-ago value to $3.06 billion. In addition, the company's adjusted net earnings stood at $3.73 billion, or $2.12 per share, representing a marginal increase year-over-year.
Analysts expect ABT's EPS and revenue for the quarter ended September 30, 2024, to increase 5.3% and 3.9% year-over-year to $1.20 and $10.53 billion, respectively. It surpassed Street EPS and revenue estimates in each of the trailing four quarters. Over the past year, the stock has gained 17.7% to close the last trading session at $114.01.
ABT's robust fundamentals are reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Stability. Within the same industry, it is ranked #24. To see ABT's Growth, Value, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/ABT/">click here</a>.
Stock #1: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and The Diabetes Operating Unit segment.
On September 25, 2024, MDT launched new technologies for its AiBLE spine surgery ecosystem, including innovations in imaging, robotics, and software, and announced a partnership with Siemens Healthineers to enhance spine surgery outcomes.
In terms of the trailing-12-month levered FCF margin, MDT's 15.06% is 878.2% higher than the 1.54% industry average. Its 27.67% trailing-12-month EBITDA margin is 334.6% higher than the 6.37% industry average. Similarly, the stock's 19.57% trailing-12-month EBIT margin is 592.2% higher than the 2.83% industry average.
MDT's net sales for its first quarter ended July 26, 2024, increased 2.8% from the prior-year period to $7.92 billion. The company's non-GAAP operating profit grew 2.3% over the prior-year quarter to $1.95 billion. In addition, its attributable net income rose 31.7% from the year-ago value to $1.04 billion, and its non-GAAP EPS stood at $1.23, up 2.5% year-over-year.
For the quarter ending October 31, 2024, MDT's revenue is expected to increase 3.6% year-over-year to $8.27 billion. Its EPS for the quarter ending January 31, 2025, is expected to grow 5.6% year-over-year to $1.37. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 14.9% to close the last trading session at $90.03.
MDT's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
MDT has a B grade for Value and Stability. It is ranked #18 in the Medical - Devices &amp; Equipment industry. <a href="https://stocknews.com/stock/MDT/">Click here</a> to access additional ratings of MDT for Growth, Momentum, Sentiment, and Quality.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;

<hr />
ABT shares were trading at $113.37 per share on Tuesday afternoon, down $0.64 (-0.56%). Year-to-date, ABT has gained 4.56%, versus a 20.57% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/abt-mdt-bdx-3-medtech-stocks-to-watch-as-innovation-in-healthcare-soars/>3 MedTech Stocks to Watch as Innovation in Healthcare Soars</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 MedTech Stocks to Watch as Innovation in Healthcare Soars

Wells Fargo's 'Value Equity' stocks: VZ, AZO, KR, and more

Wells Fargo's 'Core' stocks: GOOGL, HD, KO, and more

Medtronic issues recall for MiniMed insulin pumps over battery issues

Dividend Champion, Contender, And Challenger Highlights: Week Of October 6

In a report released today, Lee Hambright from Bernstein maintained a Buy rating on Medtronic (MDT – Research Report), with a price target of $96.0...

Bernstein Sticks to Its Buy Rating for Medtronic (MDT)

ClearBridge Value Strategy Q3 2024 Commentary

Buy 4 October Dividend Aristocrats & Watch 10

Medtronic: Undervalued Dividend Aristocrat With High Margins

Medtronic raised to outperform by RBC on valuation, fundamentals

AAPL

AESI

ALRS

AMAT

AMCR

AROW

ATKR

AVGO

AVNT

BIIB

BSVN

CHKP

CMCSA

CSCO

EADSF

EPRT

EVBN

EXPE

FAST

FLIC

FNLC

FRFHF

GILD

GNTY

GOOGL

HLAN

INTU

JJSF

JOUT

KVUE

LSTR

MAIN

MCHP

MDLZ

MRVL

MSFT

MUSA

NXPI

OFLX

ORCL

PAYX

PCAR

PODD

SBUX

SFBS

SLGN

SNDR

SOLV

SOMC

STLD

SWKS

TMUS

TNDM

TOWN

TRNO

TROW

ULTA

WASH

XRAY

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

Medtronic reports first quarter fiscal 2025 financial results

PaceMate® Acquires Medtronic Paceart Optima™ System, Bringing Complementary Capabilities to Cardiac Data Management

Medtronic chairman and CEO Geoff Martha to speak at the Wells Fargo Healthcare Conference

Medtronic expands AiBLE™ spine surgery ecosystem with new technologies and Siemens Healthineers partnership

New clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally

How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

GI Alliance Collaborates with Medtronic to Introduce GI Genius™ AI Technology for Enhanced Colon Polyp Detection

Voluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life

Comments

Medtronic

Actualités

Dernières nouvelles pour Medtronic (NYSE:MDT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL